Denosumab and Teriparatide Study (DATA-HD and DATA-EX)

Completed · Phase 4

Conditions studied: Postmenopausal Osteoporosis

In brief

The aim of the study is to assess the effect of an antiresorptive medication in combination with standard dose or alternate dose teriparatide. The study extension will evaluate the effect of one-dose of zoledronic acid after the teriparatide/denosumab combination.

Key facts

Study ID

NCT02176382

Run by

Massachusetts General Hospital

People needed

76

Starts

2014-08-01

Expected to finish

2020-02-01

Last updated by the study team

2021-02-09

Who can join

Age: 45 and older. Sex: female. Healthy volunteers: accepted.

You may qualify if…

• women aged 45+
• postmenopausal
• osteoporotic with high risk of fracture

You may not qualify if…

• no significant previous use of bone health modifying treatments

Where it is running

• Massachusetts General Hospital — Boston, Massachusetts, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.